# EDGAR Filing Document

**Accession Number:** 0001593899
**File Stem:** 0001193125-26-182340
**Filing Date:** 2026-4
**Character Count:** 4456
**Document Hash:** d1963ca25b0d0f527252848e6fd6748e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-182340.hdr.sgml**: 20260427

**ACCESSION NUMBER**: 0001193125-26-182340

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260427

**DATE AS OF CHANGE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Atea Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001593899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 460574869
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39661
- **FILM NUMBER:** 26901832

**BUSINESS ADDRESS:**
- **STREET 1:** 225 FRANKLIN STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** (857) 284-8891

**MAIL ADDRESS:**
- **STREET 1:** 225 FRANKLIN STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the Securities <br>Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**ATEA PHARMACEUTICALS, INC.**

(Name of Registrant as Specified In Its Charter)

_____________________________________________________________________________________________<br>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![img195764037_0.jpg](img195764037_0.jpg)

Your Vote Counts! ATEA PHARMACEUTICALS, INC. 2026 Annual Meeting Vote by June 17, 2026 11:59 PM ET ATEA PHARMACEUTICALS, INC. 225 FRANKLIN STREET, SUITE 2100 BOSTON, MA 02110 V93924-P52208 You invested in ATEA PHARMACEUTICALS, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote Virtually at the Meeting\* June 18, 2026 9:00 AM, EDT Smartphone users Point your camera here and vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/AVIR2026 \*Please check the meeting materials for any special requirements for meeting attendance.

------

![img195764037_1.jpg](img195764037_1.jpg)

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. Election of Class III Directors For Nominees: 01) Jerome Adams, MD, MPH 02) Howard Berman, PhD 03) Barbara Duncan 2. Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. For NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". V93925-P52208

------